A nano-cocktail of the PARP inhibitor talazoparib and CDK inhibitor dinaciclib for the treatment of triple negative breast cancer

Autor: Paige Baldwin, Shicheng Yang, Adrienne Orriols, Sherrie Wang, Needa Brown, Srinivas Sridhar

Publikováno v: Cancer Nanotechnology, Vol 15, Iss 1, Pp 1-16 (2024)

Abstract Background The addition of the cyclin dependent kinase inhibitor (CDKi) dinaciclib to Poly-(ADP-ribose) polymerase inhibitor (PARPi) therapy is a strategy to overcome resistance to PARPi in tumors that exhibit homologous recombination (HR) d

Externí odkaz: https://doaj.org/article/bcb38076fd6e4bebba02ff716de87352

Heterotargeted Nanococktail with Traceless Linkers for Eradicating Cancer.

Autor: Sui B; Department of Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, 715 Sumter, Columbia, SC 29208, United States., Cheng C; Department of Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, 715 Sumter, Columbia, SC 29208, United States., Wang M; Department of Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, 715 Sumter, Columbia, SC 29208, United States., Hopkins E; Department of Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, 715 Sumter, Columbia, SC 29208, United States., Xu P; Department of Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, 715 Sumter, Columbia, SC 29208, United States.

Publikováno v: Advanced functional materials [Adv Funct Mater] 2019 Dec 12; Vol. 29 (50). Date of Electronic Publication: 2019 Sep 16.